Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
c-ATT regimen
- Development stage
- Phase 3
- Lead developer
- Sun Yat-sen University
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The "c-ATT" regimen is a sequential chemotherapy protocol designed for the treatment of high-risk T-cell lymphoma. It integrates three distinct chemotherapy combinations: CHOPB, IMVP-16, and DHAP. CHOPB typically includes cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin. IMVP-16 is composed of ifosfamide, methotrexate, and etoposide. DHAP consists of dexamethasone, high-dose cytarabine, and cisplatin. This multi-agent approach aims to maximize therapeutic efficacy by targeting cancer cells through diverse mechanisms, including DNA damage, inhibition of DNA synthesis, and disruption of cell division, which is crucial for managing aggressive T-cell lymphomas.
02
Targets
DNATOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TS (Thymidylate synthase)DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on c-ATT regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on c-ATT regimen.